Report: More than half of the world's population will be overweight/obese by 2035

Published Date: 08 Mar 2023

The World Health Organization's 2023 Atlas predicts that 51% of the world's population, or more than 4 billion people, will be overweight or obese within the next 12 years.

Read Full News

Latest News

Novel Monoclonal Antibody Shows Benefit in Cushing Disease

The anti-adrenocorticotropic hormone antibody asedebart normalized urinary free cortisol in 7 of 8 study participants.

GLP-1s Aren’t a Solo Act. They Need Comprehensive Planning

Lifestyle changes, tracking, and support should go hand-in-hand with weight loss drugs.

AI Eye Scan Cuts Unneeded Diabetes Macular Edema Referrals

An AI-based OCT system integrated into standard diabetic retinopathy screening pathways reduces unwarranted referrals for diabetic macular edema, a recent study shows.

Neumora Scraps Depression Drug Development After Repeated Trial Failures

Neumora Therapeutics will abandon the development of its experimental depression drug following the latest trial failures and ⁠said it would cut 35% of its workforce,...

Chronic Opioid Use Raises Risk for Endocrinopathies

Possible complications include adrenal insufficiency, hypogonadism, hyperprolactinemia, hospitalization, and mortality.

Teplizumab Approved for Pediatric Stage 3 Type 1 Diabetes

The drug was previously approved for stage 2 T1D.

Todays Updates

Inside the Major Findings From the NHS-Galleri Trial

The largest randomized study of a multicancer blood test found no reduction in late-stage cancers, while raising new questions about stage shift, mortality benefit, and population screening.

Talquetamab Combos Show Survival Benefit in r/r Myeloma

Interim findings from the phase 3 MonumenTAL-3 trial highlight overall and progression-free survival as well as response rates compared with standard therapy.

Todays Updates

Inside the Major Findings From the NHS-Galleri Trial

The largest randomized study of a multicancer blood test found no reduction in late-stage cancers, while raising new questions about stage shift, mortality benefit, and population screening.

Talquetamab Combos Show Survival Benefit in r/r Myeloma

Interim findings from the phase 3 MonumenTAL-3 trial highlight overall and progression-free survival as well as response rates compared with standard therapy.

Latest News

The anti-adrenocorticotropic hormone antibody asedebart normalized urinary free cortisol in 7 of 8 study participants.

Lifestyle changes, tracking, and support should go hand-in-hand with weight loss drugs.

An AI-based OCT system integrated into standard diabetic retinopathy screening pathways reduces unwarranted referrals for diabetic macular edema, a recent study shows.

Neumora Therapeutics will abandon the development of its experimental depression drug following the latest trial failures and ⁠said it would cut 35% of its workforce,...

Possible complications include adrenal insufficiency, hypogonadism, hyperprolactinemia, hospitalization, and mortality.

The drug was previously approved for stage 2 T1D.

News All Time

Older Drug Reprograms White Blood Cells, Improves Blood Sugar in Type 1 Diabetes

(This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays.)

Oral GLP-1 Orforglipron Performs Well in Phase 3 T2D Trials

Phase 3 trials of the oral nonpeptide show glycemic and weight benefit when added to glargine and compared with dapagliflozin and oral semaglutide, but with somewhat lower tolerability.

GLP-1s Tied to Musculoskeletal Benefits in Obesity

Use of GLP-1s vs other antiobesity medications is linked to decreased risk for osteoporosis, fractures, disk degeneration, and osteoarthritis in adults with obesity.

AI Tool Detects Occult Pancreatic Cancer Months in Advance

A new AI model reliably identifies hidden pancreatic ductal adenocarcinoma on routine CT scans months before the clinical diagnosis of the disease.

Use Of GLP-1 Drugs Early in Pregnancy Should Not Cause Alarm, Analysis Suggests

Use of GLP-1 drugs for diabetes or obesity early in the first trimester of pregnancy, before a woman realizes she is pregnant, is ⁠not a cause for alarm, a large new data...

Study Finds No Link Between Semaglutide and AMD Risk

Compared with other glucose-lowering drugs, semaglutide is not associated with the risk for neovascular age-related macular degeneration in adults with type 2 diabetes.

Can GLP-1s Curb Cancer Progression?

A real-world analysis links GLP-1s to substantially lower rates of metastatic progression in four cancers associated with obesity and/or diabetes — but experts urged caution to interpret the findings.

Skin Disorders in Transgender Patients: Treatment Tips

Dermatologists highlight the risks for acne, hair loss and unwanted hair, and melasma, as well as recent data on hidradenitis suppurativa.

Weekly and Monthly Berobenatide Show Weight, A1c Benefits

The long-acting GLP-1 drug had good overall tolerability with some GI bumps in weekly-to-monthly transition, while the A1c benefits raise hopes of a potential ‘game changer’ for T2D.

Roche Obesity Drug Helps Patients Shed 22.7% Of Weight in Mid-stage Trial

Roche said on Friday that patients lost 22.7% of their body weight in a mid-stage trial of its dual-acting experimental obesity ⁠drug, with more than a quarter of those who...

Wearables Generate the Data: What's Next for Chronic Care?

Wearable devices are moving beyond fitness tracking, providing clinicians with real-world data that may improve monitoring and continuity of care in chronic disease.

Beyond BMI: New Score Stratifies Obesity Risk

BMI, while useful, is insufficient to identify patients at the highest risk for obesity-related complications. A new tool may help clinicians better stratify risk and target treatment.

Tango Therapeutics' Pancreatic Cancer Drug Combo Shows Promise in Study

Tango Therapeutics said on Monday an experimental drug combination showed strong early results in a small study of patients ⁠with advanced pancreatic cancer and that it...

Liver-Directed Insulin: A New Way to Reduce Hypoglycemia?

Study findings suggest that a liver-targeted formulation of fast-acting insulin may reduce the risk for hypoglycemia in patients with type 1 diabetes.

Moving Beyond GLP-1s: Preclinical Acceleration, Innovation

Next-generation obesity therapeutics aim to counter weight rebound, decrease side effects, and support weight maintenance.

Dual Incretin Agonist Survodutide Benefits Liver in Phase 3

The glucagon receptor/GLP-1 receptor dual agonist reduces weight, visceral fat, and liver fat.

Recommended News For You

Preoperative MRI is useful for identifying additional disease in breast cancer patients with nodes positive.

For the creation of cutting-edge targeted radionuclide therapies in oncology, Bayer and Bicycle Therapeutics work together.

Pivotal Studies in Double-Expressor DLBCL Yield Divergent Results

Researchers found that patients undergoing chemotherapy had a higher risk of mixed infections and should begin antibiotic therapy right away.

Researchers investigate risk of developing multiple primary cancers after surviving bowel cancer

Mezigdomide Combinations Show Promise in Multiple Myeloma

ASCO: GLP-1 receptor agonists may reduce risk for obesity-related cancer, all-cause death

Recommended Articles For You

The Latest Research on Basal Cell Carcinoma: New Developments in Diagnosis and Cure  

Improving TIVAP Use: Review of Standardization and Optimization Practices 

Harnessing Artificial Intelligence in Oncology: Innovations in Diagnosis, Treatment, and Patient Care 

Understanding Acute Intermittent Porphyria: Symptoms, Diagnosis and Treatment 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

What Could This Exploratory 5-Year Survival Data in Adjuvant NSCLC Treatment Mean?

2.

FDA Approves Monthly Dosing of Rybrevant Faspro for NSCLC

3.

Capivasertib Wins Metastatic Prostate Cancer Approval

4.

A healthier lifestyle after bowel screening shown to prevent bowel cancer

5.

Worse Outcomes After Esophagectomy at Private Equity-Owned Hospitals

1.

Transformative Insights in Oncology in Daily Practice

2.

Thyroidectomy & Survival: Highlights from ASCO 2025 and Current U.S. Findings

3.

Neoadjuvant Radiotherapy & Endocrine Therapy in ER+ Breast Cancer Treatment

4.

Predicting Incidental Prostate Cancer in BPH Surgery Patients

5.

Exploring the Potential of Cytologic Atypia in Cancer Diagnosis

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

International Lung Cancer Congress®

1.

Newer Immunotherapies for Myeloma- A Comprehensive Overview- Part II

2.

An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion

3.

Current Cancer Scenario in India- Importance of Genomic Testing & Advancement in Diagnosis and Treatment

4.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part III

5.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot